References
- Gertz MA, Hayman SR, Buadi FK. Transplantation for IgM amyloidosis and IgM myeloma. Clin Lymphoma Myeloma 2009;9:77–9
- Wechalekar AD, Lachmann HJ, Goodman HJ, Bradwell A, Hawkins PN, Gillmore JD. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood 2008;112:4009–16
- Palladini G, Foli A, Russo O, Milani P, Obici L, Lavatelli F, Merlini G. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone. Clin Lymphoma Myeloma Leuk 2011;11:143–5
- Sanchorawala V, Blanchard E, Seldin DC, O'Hara C, Skinner M, Wright DG. AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes. Am J Hematol 2006;8:692–5
- Gertz MA, Buadi FK, Hayman SR. IgM amyloidosis: clinical features in therapeutic outcomes. Clin Lymphoma Myeloma Leuk 2011;11:146–8
- Palladini G, Russo P, Bosoni T, Sarais G, Lavatelli F, Foli A, Bragotti LZ, et al. AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity. Clin Lymphoma Myeloma 2009;9:80–3
- Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541–9
- Landgren O, Staudt L. Letter to the editor: MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med 2012;367:2255–6
- Treon, SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med 2012;367:826–33
- Avet-Loiseau H, Garand R, Lode L, Harousseau JL, Bataille R; Intergroupe Francophone du Myélome. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 2003;101:1570–1